Drug maker Alexion has announced 3 new US patents for its eculizumab (Soliris), a first-in-class monoclonal antibody that specifically binds to the complement protein C5. Additionally, the drug gained the European Commission’s approval for the treatment of refractory generalized myasthenia gravis.
Drug maker Alexion has announced 3 new US patents for its eculizumab (Soliris), a first-in-class monoclonal antibody that specifically binds to the complement protein C5. The new patents, directed to composition of matter, pharmaceutical formulations, and methods of treatment, will extend protection for the highly expensive drug until 2027. Eculizumab is approved by the FDA for the treatment of paroxysmal nocturnal hemoglobinuria (a rare, life-threatening disease of the blood characterized by destruction of red blood cells, presence of blood clots, and impaired bone marrow function) and atypical hemolytic uremic syndrome (a rare disease that causes abnormal blood clots to form in the small blood vessels in the kidneys).
“Alexion is the leader in complement biology and has invested decades of ground-breaking research and development in Soliris. We continue to strengthen our patent portfolio around this unique complement inhibitor,” said Ludwig Hantson, Alexion’s CEO. “These new patents work in concert with other patents and regulatory exclusivities to protect Soliris in all indications.” Soliris, with its list price of over $500,000 per patient per year, is among the most expensive drugs in the market. FiercePharma reports that the drug’s sales could reach $5.6 billion by 2020.
The 3 new patents protecting Alexion’s product may be designed to stave off competition from Amgen; the rival drug maker is currently developing a biosimilar eculizumab, ABP 959. Amgen recently completed data collection in a randomized, double-blind, single-dose, 3-arm, parallel group study conducted in Australia. The trial, conducted in 217 healthy male volunteers, seeks to demonstrate the pharmacokinetic similarity of biosimilar candidate ABP 959 and the reference eculizumab.
In addition to its new US patent protection, Alexion announced yesterday that it has gained the European Commission’s (EC) approval for a new indication for eculizumab. The EC granted an extension of the indication for eculizumab for the treatment of adult patients with refractory generalized myasthenia gravis (MG), a rare, autoimmune, neuromuscular junction disorder.
The EC approval follows review of data from the phase 3 REGAIN study, which did not meet its primary efficacy endpoint of change from baseline in the myasthenia gravis—activities of daily living profile (MG-ADL) total score.
Despite the fact that the study missed its endpoint, patient groups praised the results. Nancy Law, CEO of the Myasthenia Gravis Foundation of America, said, “People with MG need more and better treatment options, especially for those with refractory generalized MG, whose extreme muscle weakness can be devastating and even life-threatening. We look forward to advocating for and supporting patients with refractory MG who have a tremendous unmet need.”
Alexion has filed a supplemental Biologics License Application with the FDA, seeking an extension of Soliris’ indications for the treatment of MG.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
The Biosimilar Void: 90% of Biologics Coming Off Patent Will Lack Biosimilars
February 5th 2025Of the 118 biologics losing exclusivity over the next decade, only 10% have biosimilars in development, meaning a vast majority of biologics have no pipeline, which limits savings potential for the health care system.
The Banking of Biosimilars: Insights From a Leading Health Economist
February 4th 2025Biosimilars have the potential to reduce health care costs and expand patient access, but economic and policy barriers affect adoption, explored James D. Chambers, PhD, MPharm, MSc, associate professor at the Tufts Medical Center Institute for Clinical Research and Health Policy Studies, in an interview.